

---

# 5.21.088

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 31, 2017
<b>Subject:</b>	Kisqali	<b>Page:</b>	1 of 6

---

**Last Review Date:** March 6, 2026

---

## Kisqali

### Description

Kisqali (ribociclib), Kisqali Femara Co-Pack (ribociclib & letrozole)

### Background

Kisqali (ribociclib) is a kinase inhibitor that inhibits cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). In vitro, ribociclib decreased pRb phosphorylation leading to arrest in the G1 phase of the cell cycle and reduced cell proliferation in breast cancer cell lines. Combination of ribociclib and antiestrogen (e.g., letrozole) resulted in increased tumor growth inhibition compared to each drug alone. Additionally, the combination of ribociclib and fulvestrant resulted in tumor growth inhibition in an estrogen receptor positive breast cancer xenograft model (1-2).

### Regulatory Status

FDA-approved indications: Kisqali is a kinase inhibitor indicated: (1)

1. in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.
2. for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
  - a. an aromatase inhibitor as initial endocrine-based therapy; or
  - b. fulvestrant as initial endocrine-based therapy or with disease progression following endocrine therapy.

FDA-approved indications: Kisqali Femara Co-Pack, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated: (2)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 31, 2017
<b>Subject:</b>	Kisqali	<b>Page:</b>	2 of 6

---

1. for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.
2. as initial endocrine-based therapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer therapy.

Monitor electrocardiograms (ECGs) and electrolytes prior to initiation of treatment with Kisqali. Repeat ECGs at approximately Day 14 of the first cycle and at the beginning of the second cycle, and as clinically indicated. Monitor electrolytes at the beginning of each cycle for 6 cycles, and as clinically indicated. Avoid using Kisqali with drugs known to prolong QT interval and/or strong CYP3A inhibitors (1).

Increases in serum transaminase levels have been seen with the use of Kisqali. Perform liver function tests (LFTs) before initiating therapy with Kisqali. Monitor LFTs every 2 weeks for first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. Based on severity of transaminase elevation, Kisqali may require dose interruption, reduction, or discontinuation (1).

Neutropenia was highly reported with the use of Kisqali. Perform complete blood count (CBC) prior to initiating therapy with Kisqali. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated (1).

The safety and effectiveness of Kisqali have not been established in pediatric patients (1).

### **Related policies**

Ibrance, Verzenio

### **Policy**

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Kisqali may be considered **medically necessary** if the conditions indicated below are met.

Kisqali may be considered **investigational** for all other indications.

### **Prior-Approval Requirements**

**Age** 18 years of age or older

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 31, 2017
<b>Subject:</b>	Kisqali	<b>Page:</b>	3 of 6

---

## Diagnoses

Patient must have **ONE** of the following:

1. Stage II or III early breast cancer at high risk of recurrence
  - a. Used for adjuvant treatment
  - b. **Kisqali only:** used in combination with an aromatase inhibitor
2. Advanced or metastatic breast cancer
  - a. **Kisqali only:** Patient has **ONE** of the following:
    - i. Used in combination with an aromatase inhibitor as initial endocrine-based therapy
    - ii. Used in combination with Faslodex (fulvestrant) as initial endocrine-based therapy or following disease progression on endocrine therapy
  - b. **Kisqali Femara Co-Pack only:** used as initial endocrine-based therapy

**AND ALL** of the following:

1. Hormone receptor (HR)-positive
2. Human epidermal growth factor receptor 2 (HER2)-negative
3. Prescriber agrees to treat with a luteinizing hormone-releasing hormone (LNRH) agonist if clinically indicated
4. Prescriber agrees to monitor liver function tests (LFTs), electrocardiograms (ECGs), complete blood count (CBC), and electrolytes prior to initiation of treatment and before each cycle as clinically indicated

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

## Diagnoses

Patient must have **ONE** of the following:

1. Stage II or III breast cancer
  - a. **Kisqali only:** used in combination with an aromatase inhibitor
2. Advanced or metastatic breast cancer
  - a. **Kisqali only:** Patient is using in combination with **ONE** of the following:
    - i. Aromatase inhibitor

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 31, 2017
<b>Subject:</b>	Kisqali	<b>Page:</b>	4 of 6

---

ii. Faslodex (fulvestrant)

**AND ALL** of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to treat with a luteinizing hormone-releasing hormone (LNRH) agonist if clinically indicated
3. Prescriber agrees to monitor liver function tests (LFTs), electrocardiograms (ECGs), complete blood count (CBC), and electrolytes before each cycle as clinically indicated

## Policy Guidelines

### Pre – PA Allowance

None

### Prior - Approval Limits

**Duration** 12 months

### Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Kisqali (ribociclib) and Kisqali Femara Co-Pack (ribociclib/letrozole) are indicated for the treatment of patients with HR-positive, HER2-negative stage II, III, or advanced or metastatic breast cancer. Liver function tests, electrocardiograms, complete blood count, and electrolytes are important parameters to monitor in these patients due to potential side effects. The safety and effectiveness of Kisqali have not been established in pediatric patients (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Kisqali while maintaining optimal therapeutic outcomes.

### References

1. Kisqali [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2025.

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 31, 2017
<b>Subject:</b>	Kisqali	<b>Page:</b>	5 of 6

2. Kisqali Femara Co-Pack [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2025.
3. NCCN Drugs & Biologics Compendium<sup>®</sup> Ribociclib 2026. National Comprehensive Cancer Network, Inc. Accessed on January 12, 2026.

### Policy History

Date	Action
March 2017	New addition to PA
July 2017	Annual editorial review Addition of the requirement of prescriber agrees to monitor liver function tests (LFTs), electrocardiograms (ECGs) and electrolytes before each cycle as clinically indicated Addition of Kisqali Femara Co-Pack
December 2017	Annual review
March 2018	Annual review
August 2018	Addition of requirement of female gender, use in combination with fulvestrant in postmenopausal, used in combination with aromatase inhibitors as initial endocrine therapy
September 2018	Annual editorial review
March 2019	Removed postmenopausal from Kisqali Femara Co-Pack requirements
June 2019	Annual review
December 2019	Annual review and reference update
June 2020	Annual review and reference update
June 2021	Annual review and reference update
January 2022	Per package insert update: removed requirement of female gender and revised Kisqali plus fulvestrant requirement so only female patients must be postmenopausal. Added requirement "Prescriber agrees to treat with a luteinizing hormone-releasing hormone (LNRH) agonist if clinically indicated"
March 2022	Annual review and reference update
September 2022	Annual review and reference update
June 2023	Annual review and reference update
March 2024	Annual review and reference update
June 2024	Annual review and reference update
August 2024	Per PI update, removed requirement that female patients be postmenopausal when using Kisqali with fulvestrant. Per FEP, added requirement to monitor CBC
October 2024	Per PI update, added indication of stage II and III breast cancer

# 5.21.088

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 31, 2017
<b>Subject:</b>	Kisqali	<b>Page:</b>	6 of 6

---

December 2024	Annual review and reference update
March 2025	Annual review and reference update
June 2025	Annual review and reference update
March 2026	Annual review and reference update

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.**